My lab aims to understand the basic mechanisms controlling DNA replication in mammalian cells and how disruption of this process leads to genomic instability and cancer.
Our research aims to understand the epigenetic regulation of transposable elements and how their dysregulation contributes to the generation and development of cancer. In particular, we investigate their roles as gene regulators and triggers of anti-tumour immunity in blood cancers.
Our group studies changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
The central aim of our laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient leukaemia therapies. We also focus on understanding haematopoietic stem cell biology with the hope to harness this knowledge for expanding them for therapeutic purposes.
My lab utilises state-of-art multi-omics methodologies to study how protein synthesis is dysregulated in cancer cells, and how this dysregulation contributes to various stages of cancer progression.
My lab aims to understand the mechanisms that underlie numerical and structural chromosome aberrations in cancer at a molecular level, which also involves understanding how normal cells replicate and segregate their genomes.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
My lab aims to understand the alterations in metabolism that take place in cancer and investigate whether extrinsic factors, such as diet, influence cancer metabolism and disease trajectory. We then want to uncover whether these dependencies can be exploited therapeutically.
My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes.
Our research focuses on how the cytoskeleton of cancer cells regulates transcriptional rewiring during tumour growth and dissemination. We aim to understand how such rewiring affects the tumour microenvironment.
My research focuses on kinase biology and how kinase signalling pathways are hijacked in cancer. We combine computational biology with proteomics and cell biology to uncover novel ways to target these dysregulated networks.
My group studies how RNA-mediated mechanisms, in particular long noncoding RNAs, regulate cell division and how dysregulation of these processes leads to genome instability and cancer.
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
I am a clinical collaborator in numerous laboratory-based studies particularly the localisation of Lipiodol in Hepatocellular carcinomas, inflammatory and immune responses to surgery, and tumour-stroma interactions in pancreatic carcinoma. Clinical areas of interest have been video consultations in tertiary care, surgery for pancreatic tumours (especially NETs) and liver tumours, and tissue banking.
My research focuses on investigating the roles of DNA Polymerase Epsilon (Pol ε) in nucleosome assembly. Using a range of biochemical and biophysical techniques (including LC-MS, Cryo-EM), my aim is to elucidate the structural analysis of the interaction between DNA Pol ε and parental histones H3-H4 at replication fork.
My research investigates the functional relevance of RNA-binding proteins (RBPS) in normal haematopoiesis and acute myeloid leukaemia (AML) pathogenesis.
My research investigates the mechanisms of sensitisation to PARP and ATR inhibitors and how dysfunction of normal DNA replication leads to genome instability and cancer.
My research investigates how centrosome amplification in breast cancer impacts angiogenesis and the tumour microenvironment, and how this can be targeted as a potential cancer therapy.
My research aims to understand the mechanisms through which long noncoding RNAs can control genome stability in cancer.
My research focuses on understanding how centrosome amplification impacts tumour angiogenesis and how this can be targeted to develop new cancer therapies.
My research is focused on studying the molecular mechanisms of integrin αvβ6-driven pancreatic ductal adenocarcinoma (PDAC) progression and metastasis.
My research projects involve identifying tumour suppressors involved in regulating the hypoxic response and metabolic stress, with the aim to identify novel targeted therapies against these.
My research activity aims to characterise lncRNAs involved in the maintenance of genomic stability and to understand how their dysregulation can lead to cancer development.
I am interested in unveiling and modelling the mechanisms that drive clonal haematopoiesis and exploring niche-based therapies to prevent it, as clonal haematopoiesis has been recently linked to an increase in the development of leukaemia and cardiovascular conditions.
My research focuses on understanding the relationship between chromosome instability mechanisms and tumour cells’ resistance to therapies.
My research is focused on investigating how the epitranscriptome regulates normal and malignant haematopoiesis.
My work is focused on exploiting cell cycle vulnerabilities in tumour cells, particularly the role of MASTL or Greatwall kinase in cell cycle control. My research will explore the role of MASTL in AML and whether it could be a new therapeutic target in this disease.
My main research focuses on examining the immune landscape and identifying specific immune determinants that can predict the progression from actinic keratosis, a pre-malignant lesion, to cutaneous SCC. I am analysing single cell RNA-seq data and utilizing machine learning algorithms to evaluate potential diagnostic and prognostic markers that could aid in the identification of high-risk SCC patients. The identification of these markers is critical for early detection and intervention, which can significantly improve patient outcomes.
My research focuses on exploring why ASS1 is differently expressed in human cancers and how this information may be transferred for anticancer therapy.
Our research is focused in defining the cellular interactome of haematopoietic stem cells and leukaemic stem cells inside their niches during adulthood, ageing and disease. We are also interested in the cellular and molecular mechanisms that drive clonal selection and evolution in clonal haematopoiesis.
My research employs 3D tissue models of oncogenic HPV infection to study the contribution of oncogene-induced replication stress (Oi-RS) and genomic instability to cancer initiation.
My research focuses on exploiting cell cycle vulnerabilities and signalling rewiring in tumour cells, to find new approaches to treat cancer.
My research uses microscopy to examine how microtubule post-translational modifications affect DNA damage repair and how this could be exploited to enhance chemotherapy.
My research focuses on developing novel methodology for in-cell monitoring of direct downstream kinase phosphorylation and phospho-isoform substrate specificity. This work will contribute towards enhancing our understanding of cell cycle protein signalling and elucidating the role of the activation loop in substrate switching.
My research focusses on understanding cancer-specific metabolism in acute myeloid leukaemia and targeting this metabolism to overcome therapeutic resistance. I also explore the role of diet and obesity in leukaemogenesis and response to therapy.